Matthieu Pelletier-Galarneau1,2, Paola Ferro3,4, Samuel Patterson4, Terrence D Ruddy4, Rob S Beanlands4, Robert A deKemp5. 1. Department of Medical Imaging, Institut de cardiologie de Montréal, Université de Montréal, Montreal, QC, Canada. 2. Gordon Center for Medical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. 3. San Raffaele Hospital, Milan, Italy. 4. University of Ottawa Heart Institute, University of Ottawa, 40 Ruskin Street, Ottawa, ON, K1Y 4W7, Canada. 5. University of Ottawa Heart Institute, University of Ottawa, 40 Ruskin Street, Ottawa, ON, K1Y 4W7, Canada. RAdeKemp@ottawaheart.ca.
Abstract
BACKGROUND: The objective of this study was to compare the hyperemic myocardial blood flow (MBF) and myocardial flow reserve (MFR) obtained with dobutamine to those of dipyridamole in patients referred for myocardial perfusion imaging (MPI) using 82Rb positron emission tomography. METHODS: One hundred and fifty-six patients who underwent a 82Rb PET MPI study with dobutamine stress were included. A matching cohort of patients who underwent a 82Rb PET MPI study with dipyridamole stress was created, accounting for sex, age, history of coronary artery disease (CAD), prior revascularization, CAD risk factors, body mass index, and MPI interpretation. RESULTS: Global rest MBF (median [interquartile range] 0.84 [0.64-1.00] vs 0.69 [0.59-0.85]), stress MBF (2.36 [1.73-3.08] vs 1.66 [1.25-2.06]), MFR (2.75 [2.19-3.64] vs 2.29 [1.78-2.84]), and corrected MFR (2.85 [2.14-3.64] vs 2.20 [1.65-2.75]) were all significantly higher (P < 0.0001) in the dobutamine cohort compared to the dipyridamole cohort. CONCLUSION: The results of this study suggest that dobutamine produces higher MBF compared to dipyridamole in a representative population referred to nuclear cardiology laboratories.
BACKGROUND: The objective of this study was to compare the hyperemic myocardial blood flow (MBF) and myocardial flow reserve (MFR) obtained with dobutamine to those of dipyridamole in patients referred for myocardial perfusion imaging (MPI) using 82Rb positron emission tomography. METHODS: One hundred and fifty-six patients who underwent a 82Rb PET MPI study with dobutamine stress were included. A matching cohort of patients who underwent a 82Rb PET MPI study with dipyridamole stress was created, accounting for sex, age, history of coronary artery disease (CAD), prior revascularization, CAD risk factors, body mass index, and MPI interpretation. RESULTS: Global rest MBF (median [interquartile range] 0.84 [0.64-1.00] vs 0.69 [0.59-0.85]), stress MBF (2.36 [1.73-3.08] vs 1.66 [1.25-2.06]), MFR (2.75 [2.19-3.64] vs 2.29 [1.78-2.84]), and corrected MFR (2.85 [2.14-3.64] vs 2.20 [1.65-2.75]) were all significantly higher (P < 0.0001) in the dobutamine cohort compared to the dipyridamole cohort. CONCLUSION: The results of this study suggest that dobutamine produces higher MBF compared to dipyridamole in a representative population referred to nuclear cardiology laboratories.
Authors: Robert A Dekemp; Jerome Declerck; Ran Klein; Xiao-Bo Pan; Ryo Nakazato; Christine Tonge; Parthiban Arumugam; Daniel S Berman; Guido Germano; Rob S Beanlands; Piotr J Slomka Journal: J Nucl Med Date: 2013-02-27 Impact factor: 10.057
Authors: Timothy M Bateman; Vasken Dilsizian; Rob S Beanlands; E Gordon DePuey; Gary V Heller; David A Wolinsky Journal: J Nucl Cardiol Date: 2016-10 Impact factor: 5.952
Authors: Milena J Henzlova; W Lane Duvall; Andrew J Einstein; Mark I Travin; Hein J Verberne Journal: J Nucl Cardiol Date: 2016-06 Impact factor: 5.952
Authors: Mireille Lortie; Rob S B Beanlands; Keiichiro Yoshinaga; Ran Klein; Jean N Dasilva; Robert A DeKemp Journal: Eur J Nucl Med Mol Imaging Date: 2007-07-07 Impact factor: 9.236